Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
15 mars 2023 08h30 HE
|
Prelude Therapeutics, Inc.
Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR)...
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
15 mars 2023 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial...
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
01 mars 2023 08h30 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
09 févr. 2023 09h05 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will...
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 08h00 HE
|
Prelude Therapeutics, Inc.
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5...
Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
06 sept. 2022 08h00 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be...
Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
09 août 2022 08h00 HE
|
Prelude Therapeutics, Inc.
Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5...